Date/Time
Date(s) - 10/11/2016 - 12/11/2016
All Day
Location
Madrid
Categories
Title: “Go for it – the many flavors of investigative dermatology”
Supported by educational grants from:
Objectives
The goal of this initiative is to encourage young gifted dermatologists to further pursue their academic careers through guidance and mentoring of established scientists in the field. Besides scientific sessions, there is a strong emphasis on encouraging young people to network and to exchange ideas. The ESDR is convinced that the Academy is a vital platform for developing European research networks and to foster tomorrow’s leaders in dermatology. The future leaders academy is an excellent opportunity for sponsoring companies to establish sound professional relationships with the next generation of leaders in dermatology.
Applications are reviewed on scientific merit by the ESDR Scientific Program Committee.
General Information
- Participants must be 40 years old or under by 1 November 2016. Exceptions may be made for career breaks, maternity/paternity leave etc
- ESDR covers accommodation costs for all participants and travel costs for ESDR members. If you are not a member you may apply prior to the Academy
- Particants must committ to staying for the entire duration of the Academy
- All attendees give oral presentations of their work and be expected to attend mentoring events
- Past participants are not eligble for consideration
- Residents outside Europe are not eligble for consideration unless they are relocating to Europe within 6 months of the end of the Academy
| Thursday 10 November 2016 | |
| 10.00-12.30 | Registration |
| 12.30-13.30 | Lunch (seated – mentors/mentees matched) |
| 13.30-14.30 | Welcome Michael Hertl (Germany), Menno de Rie (The Netherlands) |
| 14.30-15.00 | Keeping epidermal gene expression under control in health and disease Caterina Missero (Italy) |
| 15.00-16.30 | Oral Presentations by Mentees (10 minutes plus 5 minutes discussion)
15.00-15.15 Exploring the pathogenesis of alopecia areata 15.15-15.30 The role of Polycomb Repressive Complexes in epidermal differentiation 15.30-15.45 Unusual phenotypes in epidermolytic ichthyosis 15.45-16.00 Early genetic and epigenetic events in skin cancer development 16.00-16.15 Light-independent pro-inflammatory and pro-oxidant effects of purified human hair melanins on keratinocyte cell cultures 16.15-16.30 Complement system in cutaneous squamous cell carcinoma |
| 16.30-17.00 | Coffee Break |
| 17.00-17.30 | Tolerance in mice and men Kerstin Steinbrink (Germany) |
| 17.30-18.20 | Oral presentations by industry partners
Abbvie, Celgene |
| 18.20-19.05 | Oral Presentations by Mentees (10 minutes plus 5 minutes discussion)
18.20-18.35 Modelling atopic eczema for therapeutic development 18.35-18.50 Antisense oligonucleotide RNA-based therapy for epidermolysis bullosa 18.50-19.05 Innate immune sensing of TLR2/6 ligands suppresses T cell immunity by inducing myeloid-derived suppressor cells |
| 19.05-19.45 | Break |
| 19.45- | Networking Event (transfer by bus from hotel lobby at 19.45) |
| Friday 11 November 2016 | |
| 07.00-08.00 | Breakfast |
| 08.00-08.30 | Experimental investigations of melanoma immunotherapy – Adventures in serendipity Thomas Tüting (Germany) |
| 08.30-09.00 | Chances and Hurdles in Experimental Dermatology Alexander Navarini (Switzerland) |
| 09.00-10.15 | Oral Presentations by Mentees (10 minutes plus 5 minutes discussion)
09.00-09.15 Wiskott-Aldrich Syndrome: a model to study the immune pathogenesis of cancer and eczema 09.15-09.30 Novel therapeutic approaches for dystrophic epidermolysis bullosa based on an increased understanding of the disease 09.30-09.45 Dynamics of Neutrophil Extracellular Traps 09.45-10.00 Hyperactive NRAS downstream signaling induces specific transcriptome changes – esiRNA based identification of new therapeutic targets in NRAS mutant melanoma 10.00-10.15 Role of IL-36 in Acute Generalized Exanthematous Pustulosis |
| 10.15-11.15 | Coffee Break and Group Photo |
| 11.15-11.45 | Translational research dedicated to the study of melanocytesThierry Passeron (France) |
| 11.45-12.45 | Oral Presentations by Mentees (10 minutes plus 5 minutes discussion)
11.45-12.00 Genomic Aberrations in Melanocytic Tumors 12.00-12.15 Melanoma intratumor heterogeneity at the single-cell level 12.15-12.30 Mechanisms of Mast cells and T cell interactions during viral infections 12.30-12.45 The value of observational data in dermatology |
| 12.45-13.05 | Presentation by industry partner
Novartis |
| 13.05-14.15 | Lunch |
| 14.15-15.15 | Oral Presentations by Mentees (10 minutes plus 5 minutes discussion)
14.15-14.30 Recruitment and activation of proinflammatory human slanDCs by immune complexes 14.30-14.45 T lymphocytes in atopic dermatitis: New specificities, phenotypes and functions 14.45-15.00 The role of T cell subsets in autoimmune bullous diseases 15.00-15.15 Innate-like T cells in human skin: characterising the human lymphoid stress surveillance response |
| 15.15-16.05 | Presentations by industry partners
Janssen Cilag, Lilly |
| 16.05-16.30 | Coffee Break |
| 16.30- | Networking Program (departure from hotel lobby at 16.30) |
| Saturday 12 November 2016 | |
| 07.00-08.30 | Breakfast |
| 08.30-09.00 | Happy Together Peter Steijlen (The Netherlands) |
| 09.00-09.45 | Oral Presentations by Mentees (10 minutes plus 5 minutes discussion)
09.00-09.15 Gene-corrected fibroblast therapy for recessive dystrophic epidermolysis bullosa using a SIN COL7A1 retroviral vector 09.15-09.30 Using a novel MS/MS clustering algorithm to analyse tumour heterogeneity in melanoma metastasis 09.30-09.45 Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma |
| 09.45-10.15 | To D or Not to D? Mario Fabri (Germany) |
| 10.15-10.45 | My Retrospect and Your Future Mona Stahle (Sweden) |
| 10.45-12.10 | Break-out Session/Coffee Break |
| 12.10-12.50 | Presentation of Break-out Sessions to Plenum |
| 12.50-13.00 | Meeting digest and Outlook Michael Hertl (Marburg), Menno de Rie (Amsterdam) |
| 13.00 | Lunch and departures |